BQ 485

Drug Profile

BQ 485

Latest Information Update: 14 Sep 2004

Price : $50

At a glance

  • Originator Banyu
  • Class Anti-ischaemics; Antihypertensives
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cerebral vasospasm; Coronary disorders; Hypertension

Most Recent Events

  • 14 Sep 2004 Discontinued - Preclinical for Hypertension in Japan (PO)
  • 14 Sep 2004 Discontinued - Preclinical for Cerebral vasospasm in Japan (unspecified route)
  • 14 Sep 2004 Discontinued - Preclinical for Coronary disorders in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top